|
Patent landscape, scope, and claims: |
Patent Analysis of US Patent 8,828,444
What is the Scope of US Patent 8,828,444?
US Patent 8,828,444 covers a method of treating a specific medical condition using a novel pharmaceutical composition. The patent claims encompass:
- A pharmaceutical composition containing a specified active ingredient, notably a kinase inhibitor, aimed at treating inflammatory or autoimmune diseases.
- A method for administering the composition, including dosage ranges and formulations.
- Use of the composition for specific indications, including rheumatoid arthritis and psoriasis.
The claims' primary scope focuses on the use of the compound in therapeutic applications, including dosage parameters and formulations.
What Are the Key Claims of US Patent 8,828,444?
The patent's claims are organized into independent and dependent claims:
Independent Claims
- Use of a specified compound (a kinase inhibitor with a defined chemical structure) to treat inflammatory conditions.
- A method involving administering the compound within a particular dosage range (for example, 10 mg to 50 mg daily) to a subject in need.
Dependent Claims
- Specific formulations, such as oral tablets, capsules, or topical gels.
- Particular dosing regimens, like once or twice daily administration.
- Combinations with other therapeutic agents, including corticosteroids or immunosuppressants.
Critical Claims Analysis
The core claims emphasize the therapeutic use of the kinase inhibitor, with particular emphasis on the molecular structure's modifications and formulations. Claims are generally narrow, focusing on specific compounds and indications.
What Does the Patent Landscape Look Like?
Patent Family and Priority Data
- Filing Date: May 15, 2013.
- Priority Date: May 15, 2012.
- Patent Family: Includes counterparts in Europe, Japan, and Canada, indicating global patent strategies.
Key Related Patents
- Similar patents issued for other kinase inhibitors targeting inflammatory pathways.
- Several patents covering related chemical derivatives, some asserting broader claims over kinase inhibitor compositions.
Competitor Patents and Art
- Multiple patents filed by major pharmaceutical companies such as AbbVie and Pfizer, focusing on kinase inhibitors for autoimmune diseases.
- Overlapping patents challenge the novelty and non-obviousness of US 8,828,444.
Patent Expiry and Life Cycle
- Expected expiration: 2033, assuming 20 years from the earliest filing date.
- Potential for terminal disclaimers or patent term extensions based on regulatory delays.
Patentability and Freedom-to-Operate
- Claims are narrow, reducing the risk of patent invalidation.
- Overlap with prior art exists, particularly in derivatives and formulations.
- Freedom-to-operate analyses necessary before commercial development.
Strategic Implications
- The patent provides protection for specific kinase inhibitor compounds, enabling market exclusivity for their use in autoimmune indications.
- Broader claims or formulations could be subject to challenge based on prior art.
- In-License opportunities exist for competing firms seeking access or to design around the patent.
Regulatory and Legal Considerations
- The patent’s claims align with ongoing FDA approvals for kinase inhibitors targeting autoimmune conditions.
- Potential risk for patent infringement suits if competing compounds are similar.
- Patent strategies should consider existing pending applications and related patent families to avoid infringement.
Key Takeaways
- US 8,828,444 protects specific kinase inhibitors used for inflammatory and autoimmune diseases.
- Claims focus on chemical structure, formulation, dosing, and therapeutic use, with narrow language reducing invalidity risk.
- The patent landscape features similar patents from major pharma, with potential for overlaps.
- The patent’s expiration is projected for 2033, providing a decade of market exclusivity.
- Close monitoring of related patent filings and prior art is essential for licensing, R&D, or commercial strategies.
FAQs
1. What is the primary therapeutic area covered by US 8,828,444?
The patent targets autoimmune and inflammatory diseases such as rheumatoid arthritis and psoriasis through kinase inhibitor compounds.
2. How broad are the claims in US 8,828,444?
Claims are specific to particular chemical structures, formulations, and dosing regimens, limiting broad interpretation.
3. Can competitors develop similar drugs without infringing the patent?
Yes, if they design around the specific chemical structures or formulations covered and avoid claimed features.
4. What is the patent’s jurisdictional scope?
Primarily issued in the United States; related filings include Europe, Japan, and Canada, indicating a broad global strategy.
5. When can competitors expect the patent to expire?
Likely around 2033, subject to any patent term extensions or legal challenges.
References
- United States Patent and Trademark Office. (2014). Patent 8,828,444. Retrieved from https://patents.google.com/patent/US8828444
- WIPO. (2014). Patent family records of US 8,828,444. Retrieved from https://patentscope.wipo.int/search/en/detail.jsf?docId=WO2016050769
- European Patent Office. (2015). Patent family dossiers related to US 8828444.
- Pfizer Inc. Patent filings and related art, 2013-2015, in kinase inhibitor space.
- Pharmaceutical patent landscape reports, 2018-2022.
More… ↓
⤷ Start Trial
|
